Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÁøÇàµÈ ¼º¹®»óºÎ¾Ï¿¡¼­ PCR-SSCP¿¡ ÀÇÇÑ p53ÀÇ¡¡º¯ÀÌ ¾ç»ó°ú¡¡ÀÓ»óÀû¡¡ÀÇÀÇ p53 Mutations in Advanced Supraglottic Cancer

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2001³â 19±Ç 2È£ p.107 ~ 112
¼Ò¼Ó »ó¼¼Á¤º¸
È«¼º¾ð/Seong Eon Hong °­Áø¿À/¹éÇüȯ/À±°æ½Ä/Jin Oh Kang/Hyung Hwan Baik/Kyung Sik Yoon

Abstract

¸ñÀû: ÁøÇàµÈ ¼º¹® »óºÎ¾Ï ȯÀÚ¿¡¼­ p53 À¯ÀüÀÚ º¯ÀÌ ¾ç»óÀ» ÆľÇÇÏ°í ÀÌÀÇ ÀÓ»óÀû ¿¹ÈÄ ÀÎÀڷμ­ÀÇ °ü·Ã¼ºÀ» È®ÀÎÇÏ°íÀÚ ÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý: °æÈñ´ëÇк´¿ø¿¡¼­ º´±â 3 ¶Ç´Â 4ÀÇ ÁøÇàµÈ ÈĵξÏÀ¸·Î Áø´Ü ¹Þ°í ±ÙÄ¡Àû ¸ñ
ÀûÀÇ Àü ¶Ç´Â ºÎºÐ ÈĵÎÀýÁ¦¼úÀ» ½ÃÇà ¹Þ°í 4600 cGyÀÌ»óÀÇ ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº ȯÀÚ 60·Ê
Áß ÀûÀýÇÑ Á¶Á÷À» È®º¸ ÇÒ ¼ö ÀÖ¾ú´ø ȯÀÚ 26¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. Á¶Á÷ ÀϺδ ¸é¿ª ¿°»ö
À» ½ÃÇàÇÏ¿´°í ÀϺδ p53 À¯ÀüÀÎÀÚÀÇ exon 5¹øºÎÅÍ 8¹ø±îÁö PCR-SSCP ½ÃÇàÈÄ
PCR-SSCP »ó ÀÌ»ó ¼Ò°ßÀÌ Àִ ȯÀÚµéÀÇ DNA¸¦ ¿°±â ¼­¿­ ºÐ¼®ÇÏ¿´´Ù. ÀÌ °á°ú¸¦ ÀÓ»ó
Àû ¼Ò°ß°ú ºñ±³ ºÐ¼®ÇÏ¿´´Ù.
°á°ú: PCR-SSCP °Ë»ç °á°ú exon 5~8¹ø¿¡¼­ Àüü 26·Ê Áß 8·Ê(31%)¿¡¼­ º¯À̸¦ ³ªÅ¸³»¾ú
´Ù. 8·Ê ¸ðµÎ Á¡µ¹¿¬º¯À̾úÀ¸¸ç transitionÀÌ Àüü 8·Ê Áß 6·ÊÀ̾ú´Ù. Exon 5¹øÀÇ º¯ÀÌ°¡ 3
·Ê, exon 6¹øÀÇ º¯ÀÌ°¡ 4·Ê, exon 7¹øÀÇ º¯ÀÌ°¡ 1¿¹À̾ú´Ù. Àüü ȯÀÚÀÇ Æò±Õ »ýÁ¸ ±â°£Àº
67.4°³¿ù À̾ú°í p53 º¯ÀÌ°¡ ¾ø´Â ±ºÀÌ 70.2°³¿ù, p53 º¯ÀÌ°¡ ÀÖ´Â ±ºÀÌ 61.3°³¿ù·Î p53 º¯
ÀÌ°¡ ÀÖ´Â ±ºÀÇ »ýÁ¸ ±â°£ÀÌ °¨¼ÒµÇ¾î ³ªÅ¸³µÀ¸³ª µÎ ±º°£ÀÇ »ýÁ¸ ±â°£ÀÇ Åë°èÀûÀÎ À¯ÀÇÇÑ
Â÷ÀÌ´Â ¾ø¾ú´Ù(p=0.596). ȯÀÚ¸¦ º´±â ¥²°ú ¥³·Î ³ª´©¾î SSCP»ó º¯ÀÌÀÇ Â÷À̸¦ ºñ±³ÇÏ¿´´Â
µ¥ º´±â ¥²Àº ¾ç¼ºÀÌ 25%À̾ú°í º´±â ¥³´Â 36%·Î ³ªÅ¸³ª º´±â ¥³¿¡¼­ ¾à°£ ³ô°Ô ³ªÅ¸³µÀ¸
³ª Åë°èÀû Â÷ÀÌ´Â ¾ø¾ú´Ù(p=0.563). ÀÓÆÄÀý À½¼ºÀΠȯÀÚ Áß SSCP ¾ç¼ºÀº 25%À̾ú°í ÀÓÆÄÀý
¾ç¼ºÀΠȯÀÚ Áß SSCP ¾ç¼ºÀº 42%À̾úÀ¸³ª Åë°èÀû Â÷ÀÌ´Â ¾ø¾ú´Ù(p=0.437).
°á·Ð: PCR-SSCP¸¦ ÀÌ¿ëÇÑ p53 À¯ÀüÀÎÀÚ º¯ÀÌÀÇ °Ë»öÀº »ýÁ¸ ±â°£, º´±â, ÀÓÆÄÀý ÀüÀÌ µî°ú
°ü·ÃÀÌ ¾øÀ¸¸ç ¿¹ÈÄÀÎÀڷμ­ À¯¿ëÇÏÁö ¾ÊÀº °ÍÀ¸·Î ÆÇ´ÜÇÏ¿´´Ù.

Purpose: To determine the prognostic significance of p53 mutations in advanced supraglottic cancer patients.
Material and Methods: Twenty-six patients with pertinent tissue materials among 60
patients diagnosed as advanced supraglottic cancer in Kyung Hee university hospital and
received total or partial laryngectomy followed by radiation therapy were enrolled.
Immunohistochemical staining using DO7 monoclonal antibody was performed. Tumor
specimens were analyzed for p53 mutations in exons 5 through 8 by using PCR-SSCP
analysis followed by DNA sequencing of all variants.
Results: p53 mutations were present in 8 cases among 26 patiets. Mutations within exon
5 were 3 cases, exon 6 were 4 cases, and exon 7 was 1 case. Mean survival time was
70.2 months in patients without mutations, 61.3 months with mutations but there was no
statistically significant difference (p=0.596). Mutations were 25% in stage ¥² and 36% in
stage ¥³ but there was no statistically significant difference (p=0.563). Mutations were
25% in lymph node negative group and 42% in lymph node positive group but there
was no statistically significant differences (p=0.437).
Conclusion: The presence of a p52 mutation detected by PCR-SSCP is not associated
with survival, stage and lymph node status.

Å°¿öµå

p53 º¯ÀÌ; ¼º¹®»óºÎ¾Ï; ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á; ºñ¼Ò¼¼Æ÷¼º Æó¾Ï; p53 mutation; Supraglottic cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS